The present study is set up to evaluate the efficacy of a programmation by administration of
estrogen valerate during 6 or more consecutive days. In this prospective randomised trial, we
study the impact of administration of Progynova® during 6, 7,8 9 or 10 consecutive days
during the luteo-follicular transition period of the menstrual cycle.